Results from two studies demonstrate that patients at high risk of bleeding can safely be treated with Abbott's Xience everolimus-eluting coronary stent and a short course of dual-antiplatelet therapy.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?